Expansion Sees Q Chip Move to New Facility
Q Chip Ltd has officially opened its new corporate headquarters and R&D facility in Cardiff. The expansion into new headquarters marks a significant step in the steady expansion Q Chip has experienced since its foundation, according to the company.
Q Chip Ltd
In summer 2007 Q Chip successfully completed a funding round which saw it raise in excess of £2 million from existing and new shareholders. This investment is being used to expand the product range of ReaX™ encapsulated PCR reagents, Biologix™ microspheres for peptide delivery and cell encapsulation, as well as Q Chip’s proprietary MicroPlant™ microfluidic device
Commenting on the move to the new facility Executive Chairman Ken Powell stated “the management and staff of Q Chip have consistently hit all the milestones set for it by the Board and shareholders. This is a true testimony to the quality of the team. After the successful completion of a major funding round last year I believe the expansion into new headquarters provides further evidence of the momentum behind the Company and the market appetite for its products.”
Other news from the department business & finance
These products might interest you
Blotting standards and reagents by Cytiva
Western blotting standards and reagents
Blotting the course to effective detection of proteins from sample preparation to analysis
Micro-Dx™ CE IVD by Molzym
Fully automated from sample to PCR analysis
Rapid identification of bacteria and fungi without time-consuming cultivation
DNA-free Taq Polymerases and Mastermixes by Molzym
DNA-free reagents for unrivalled sensitivity in molecular biology
Purity that makes the difference
Greener Alternative Products by Merck
Sustainable laboratory products for environmentally conscious research
Over 2,500 ecological alternatives to reduce your laboratory footprint
Most read news
More news from our other portals
Last viewed contents
Pieris Receives BMBF Grant to Fund PRS-110 c-Met Antagonist Anticalin Program - Grant Supports Personalized Anti-cancer Approach on Path to Clinic
Bausch + Lomb Names Daniel M. Wechsler as Global President, Pharmaceuticals
